SCHEMBL2887785

SCHEMBL2887785

COC(=O)c1c(C(O)c2cc3ccccc3o2)n(S(=O)(=O)c2ccccc2)c2ccc(OCc3ccccc3)cc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 2/20 0.41
MAOB P27338 2/20 0.41
HTR6 P50406 1/20 0.41
HDAC1 Q13547 2/20 0.40
HDAC6 Q9UBN7 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
CASP3 P42574 1/20 0.40
SENP8 Q96LD8 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP6 Q9GZR1 1/20 0.40
ADAMTS4 O75173 1/20 0.39
BCL2 P10415 1/20 0.38
BID P55957 1/20 0.38
MCL1 Q07820 1/20 0.38
GAA P10253 4/20 0.38
LMNA P02545 3/20 0.38
MAPK1 P28482 1/20 0.38
SRD5A2 P31213 1/20 0.37
SLC16A3 O15427 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2887197 0.91 HTR6 (0.41) HTR6HDAC1HDAC6L3MBTL1CASP3
SCHEMBL2887943 0.86 MEN1 (0.42) HTR6ADAMTS4ALDH1A1
SCHEMBL2887464 0.85 EDNRA (0.39) HTR6ADAMTS4BCL2BIDMCL1
SCHEMBL12344899 0.84 SRC (0.46) ADAMTS4GAALMNAMAPK1ALDH1A1
SCHEMBL2886004 0.84 CASP3 (0.43) HTR6HDAC1HDAC6L3MBTL1CASP3
SCHEMBL2885831 0.83 MAPT (0.35) L3MBTL1ADAMTS4GAALMNAMAPK1
SCHEMBL12344893 0.79 EDNRA (0.38) BCL2BIDMCL1GAALMNA
SCHEMBL12344889 0.79 KDM4E (0.38) ADAMTS4GAALMNAALDH1A1
SCHEMBL2888688 0.78 GAA (0.41) HDAC1HDAC6L3MBTL1CASP3SENP8
SCHEMBL2886443 0.77 PDE4A (0.44) ADAMTS4BCL2BIDMCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2035429-B1 FUSED [d]PYRIDAZIN-7-ONES CEPHALON INC (US) 2012-09-19 EP disclosed
EP-2035429-B1 FUSED [d]PYRIDAZIN-7-ONES CEPHALON INC (US) 2012-09-19 EP disclosed
US-7732447-B2 such as 4-Pyridin-3-yl-2,5-dihydro-pyridazino[4,5-b]indol-1-one, used as inhibitors of vascular endothelial growth factor receptor (VEGFR) kinase, mixed lineage kinase (MLK) or cyclin-dependent kinase (CDK); treatment of angiogenic disorders and neurodegenerative diseases CEPHALON, INC. (US) 2010-06-08 US disclosed
US-7732447-B2 such as 4-Pyridin-3-yl-2,5-dihydro-pyridazino[4,5-b]indol-1-one, used as inhibitors of vascular endothelial growth factor receptor (VEGFR) kinase, mixed lineage kinase (MLK) or cyclin-dependent kinase (CDK); treatment of angiogenic disorders and neurodegenerative diseases CEPHALON, INC. (US) 2010-06-08 US disclosed
US-20070299061-A1 Fused [d]pyridazin-7-ones CEPHALON, INC. (US) 2007-12-27 US disclosed
US-20070299061-A1 Fused [d]pyridazin-7-ones CEPHALON, INC. (US) 2007-12-27 US disclosed
WO-2007149557-A1 FUSED [d]PYRIDAZIN-7-ONES CEPHALON, INC. (US) 2007-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299061-A1 Fused [d]pyridazin-7-ones CDK5, CDK5R1, CDK7 MAOA 680/4885MAOB 705/4885HTR6 1506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.